Compare Estee Lauder Companies Inc (EL) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Sanofi SA — how do they compare? Estee Lauder Companies Inc trades at $94.6 (market cap $34.17B), while Sanofi SA trades at $40.2 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 2.8× Estee Lauder Companies Inc's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Estee Lauder Companies Inc for 122 Days and Sanofi SA for 94 Days on average.
| EL | SNY | |
|---|---|---|
Market Cap | $34.17B | $95.18B |
Volume | 3,921,497 | 2,995,646 |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $52.34 |
52-Week Low | $67.23 | $39.51 |
Typical Hold Time | 122 Days | 94 Days |
Enterprise Value | $39.92B | $114.48B |
Dividend Yield | 1.48% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $94.45, up 1.17% with a bullish technical signal from moving averages. The company shows mixed fundamentals with a high P/E ratio of 188.9 but strong gross margins of 75.5%. Recent earnings beats in Q4 2025 and Q1 2026 contrast with a net loss of $1.13B in 2025. Analyst consensus is positive with 47.8% buy ratings and a $103 price target. Recent developments include AI partnerships and leadership changes.
Outlook remains cautiously optimistic as the company navigates profitability challenges while investing in digital transformation. Key opportunities include margin recovery and AI-driven growth initiatives, balanced against competitive pressures and execution risks in the beauty sector. The stock offers potential upside to analyst targets if turnaround efforts succeed.
SNY trades at $40.2, up 1.62% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported revenue of $46.72B in 2025 with a net income margin of 16.72%, and it has beaten EPS estimates for the last three quarters. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling strong pipeline development.
The outlook is mixed; analyst consensus leans hold (51.86%) with a buy rating at 44.44%, reflecting optimism on new drug launches but caution over future profit margin compression projected for 2026. Key risks include execution of the expanded Regeneron partnership and managing debt levels amid investing cash flow volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
